Regulus Therapeutics (NASDAQ:RGLS) has been under a strong bear grip, hence the stock is down -34.64% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 7.65% in the past 1 week. The stock has risen by 9.03% in the past week indicating that the buyers are active at lower levels, but the stock is down -33.59% in the past 4 weeks.
The company shares have dropped -68.27% from its 1 Year high price. On Jul 14, 2015, the shares registered one year high at $11.59 and the one year low was seen on Jun 28, 2016. The 50-Day Moving Average price is $5.06 and the 200 Day Moving Average price is recorded at $6.35.
The stock has recorded a 20-day Moving Average of 24.79% and the 50-Day Moving Average is 33.36%.
Regulus Therapeutics (NASDAQ:RGLS): stock turned positive on Friday. Though the stock opened at $3.44, the bulls momentum made the stock top out at $3.52 level for the day. The stock recorded a low of $3.39 and closed the trading day at $3.5, in the green by 2.04%. The total traded volume for the day was 618,218. The stock had closed at $3.43 in the previous days trading.
In an insider trading activity, Hagan Joseph P, COO of Regulus Therapeutics Inc. had purchased 10,000 shares on March 3, 2016 in a transaction. The price per share was $7.19 and the total amount of the disclosed transaction was $71,900.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Its microRNA provides therapeutic approach for treating diseases. The Companys Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners. Its development programs include microRNA target miR-122, miR-21, RG-012, miR-103/107, miR-19, miR-10b and miR-221. The Company under the Clinical Map Initiative is focused on advancing its clinical-stage programs, RG-101 and RG-012 in 2015. The Company achieved human proof-of-concept with RG-101 in HCV.